clinical trial · NCT05344365
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Parkinson Disease PsychosisIloperidone
brief summary
This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).
started
Jun 1, 2022
primary completion
Nov 1, 2023
completion
Nov 1, 2023
last updated
Mar 21, 2024
official title
An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol